GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have been assigned an average recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $8.86.

Several research analysts have recently weighed in on GDRX shares. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of GoodRx in a report on Friday, August 16th. Barclays reduced their price target on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Monday, November 11th. UBS Group reduced their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Finally, Citigroup reduced their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Insider Buying and Selling at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.17% of the company’s stock.

Hedge Funds Weigh In On GoodRx

Several large investors have recently modified their holdings of GDRX. Beacon Capital Management LLC bought a new position in GoodRx during the first quarter worth about $28,000. nVerses Capital LLC bought a new position in GoodRx during the third quarter worth about $33,000. Plato Investment Management Ltd bought a new position in GoodRx during the second quarter worth about $43,000. EP Wealth Advisors LLC bought a new position in GoodRx during the third quarter worth about $73,000. Finally, Sanctuary Advisors LLC bought a new position in GoodRx during the third quarter worth about $85,000. 63.77% of the stock is owned by institutional investors.

GoodRx Stock Down 0.4 %

Shares of NASDAQ:GDRX opened at $4.84 on Wednesday. GoodRx has a 52 week low of $4.09 and a 52 week high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The company has a market capitalization of $1.84 billion, a PE ratio of -161.33, a PEG ratio of 3.52 and a beta of 1.39. The company has a 50 day moving average price of $5.98 and a two-hundred day moving average price of $7.25.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.